First ever detection of avian influenza among domestic birds on P.E.I.
In a statement to The Guardian on May 21, CFIA noted that it is the first detection in domestic birds in Prince Edward Island.
'The detection is not unexpected as the virus has been circulating in wildlife and wild birds in Eastern Canada throughout the current HPAI outbreak,' read the statement.
The statement added that new cases of avian influenza are not uncommon as the risk of avian influenza for domestic poultry tends to increase during the spring and fall migration of wild birds.
'The Agency does not release specific details about the operations of individual farms in order to help protect the privacy of producers, however the Agency can confirm that this detection was at a non-commercial poultry premises,' said the statement.
The CFIA says human infections with avian influenza are rare and usually occur after close contact with infected birds or highly contaminated environments.
The CFIA has implemented a primary control zone (PCZ) for the infected premises.
'A PCZ mitigates the risk of disease spread by controlling movements of designated animals and things through the use of CFIA permits,' read the statement.
All commercial and backyard poultry producers, regardless of the size of their flocks, are encouraged to remain vigilant of HPAI and ensure they have biosecurity measures in place, said the CFIA.
These measures include:
In a statement to The Guardian on May 20, the P.E.I. Association of Exhibitions encouraged local poultry owners and exhibitors to remain vigilant and implement recommended biosecurity practices to minimize risks.
'As the situation evolves, we will provide updates to our fairs, festivals and exhibitions at which time our plans will be adjusted accordingly,' read the statement.
At this time, the association's planning for summer exhibitions remains unchanged.
'However, we recognize the importance of biosecurity measures and will continue to assess any potential impacts on events involving poultry or other birds,' read the statement.
The primary source of infection of farmed birds in Canada is most likely through contact or contamination from the wild bird population, said the CFIA.
'This includes contaminated manure, litter, clothing, footwear, vehicles, equipment, feed and water,' the statement said.
When cases of avian influenza are confirmed, CFIA says that response measures include movement restriction, disease containment and surveillance in order to control the spread and eradicate the disease.
'Quarantine and animal movement controls are placed on infected premises, and any poultry operations that may have had contact with infected premises,' said the CFIA.
Non-commercial poultry operations are premises with fewer than 1,000 birds in total, and less than 300 waterfowl.
Yutaro Sasaki is a Local Journalism Initiative reporter, a position funded by the federal government. He can be reached by email at
ysasaki@postmedia.com
and followed on X @PEyutarosasaki.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Why food recalls have increased so drastically in the last decade in Canada
Last year, it was plant-based refrigerated beverages. This summer, it's Dubai chocolate, which went from viral fame to plain old virulent, with the Canadian Food Inspection Agency (CFIA) recalling several brands due to Salmonella contamination. It's not your imagination — there are more food recalls today than a decade ago, though the number has stayed relatively stable over the past five years. Experts say the reason why comes down to a couple of key factors: improved detection methods and regulations that modernized Canada's food safety system. When Sylvain Charlebois, senior director of Dalhousie University's Agri-Food Analytics Lab (AAL), posted a graph of the number of food recalls in Canada since 2011 on social media last week, some of his followers expressed surprise and concern. The graph showed a dramatic jump from 45 recalls in 2018 to 259 in 2019, remaining well above 100 ever since (with two years surpassing 250). Our food safety culture is 'very strong,' says Charlebois, pointing to Canadians' reluctance to eat perfectly edible products past their best-before dates. Food recalls don't necessarily mean that our food system is unsafe — he sees them as a sign that it's maturing in a positive way. 'People tend to become quite nervous as soon as they see a metric that would suggest, perhaps, that things aren't going in the right direction, but they are in terms of food recalls.' Some recalls, such as the recent outbreak of Salmonella infections linked to various brands of pistachios and pistachio-containing products, such as Dubai chocolate, cause illnesses and hospitalizations, but many others are preventative. Though recalls due to microbiological hazards were the most prevalent from April 1, 2020, to March 31, 2025, they can also result from allergens, extraneous material, chemicals and other reasons. Even in a modern, effective food safety system such as Canada's, risks cannot be completely eliminated 'Even in a modern, effective food safety system such as Canada's, risks cannot be completely eliminated. When unsafe food enters the marketplace, the CFIA works with the company to ensure that the public is informed and that the recall was effective at removing products from the market,' the CFIA said in an email to National Post. 'Consumers can help protect themselves and their families by following safe food handling practices at home and staying informed about food recalls by signing up for food recall notifications.' Keith Warriner, a professor at the University of Guelph's Department of Food Science, highlights that the means of detecting outbreaks are much better than they were 10 years ago, 'if not five years ago.' Sophisticated surveillance systems and advanced techniques, such as whole genome sequencing, have made it easier to identify risks. Companies are also doing more testing, which increases the likelihood of finding something warranting a recall, says Warriner. 'Even though no outbreaks are involved, they'll do it as a precaution. And you'll see microgreen producers, for example, they've had quite a few recalls of Listeria. Even though there's been no real outbreaks of Listeria with microgreens, they preempt it because they do a lot of testing.' Not only has the science improved, but the Safe Food for Canadians Act and Food Safety Modernization Act in the United States were instituted, which Warriner says put the onus on risk management. The Safe Food for Canadians Regulations came into force in January 2019, marking what Charlebois calls a turning point, 'allowing the entire industry at all levels, whether it's municipal, provincial or federal, to run more rigorous food safety systems.' Charlebois credits the regulations for the 476 per cent increase in food recalls — classes I (high-risk), II (moderate-risk) and III (low-risk) — the AAL identified from 2018 to 2019. In 2011, less than 10 per cent of contaminated items could be source-attributed (identifying outbreaks and tracing them to products), says Warriner. Today, that number has increased to roughly 25 per cent. However, the question of whether food is safer now, with 131 recalls so far this year, than in 2011, when there were only four, is a debating point. 'One could say that an increased number of recalls means we're detecting more, and therefore it's a successful food safety management system because the net is getting tighter. But another way of looking at it is saying, 'Well, we've got all this knowledge. Surely recalls should be going down,'' says Warriner. 'Testing doesn't improve food safety. It just makes you much more aware of a problem. Whereas the interventions, i.e., actual things to decontaminate products, have lagged behind. So, the famous saying from Frank Yiannas (former deputy commissioner of food policy and response at the U.S. Food and Drug Administration), 'When detection outpaces control, you're in trouble.'' Testing is necessary to detect risks, but controlling them needs to be more than words, says Warriner. He references LGMA (the Leafy Greens Marketing Agreement), which was established in Arizona and California in the wake of the 2006 E. coli outbreak in spinach. The agreement was intended to tighten up the industry, 'but it all just became words and gestures (rather) than actual control. And that's going to be 20 years old next year.' There's also room for improvement in how the CFIA communicates food recalls to the public, says Charlebois. AI could make the process more precise and proactive by using targeted methods to identify and monitor risks. Implementing AI might mean even more recalls, affecting a smaller volume of food and reducing food waste as a result. 'I think it's reassuring to see the number of recalls we're seeing right now. But one has to think about the costs incurred in the industry because, as consumers, we eventually pay for these recalls. So, how do you make these recalls more efficient?' The world's only three Michelin-starred vegan restaurant is bringing back meat Why the French are outraged that Perrier filtered its water: 'This really is our Water-gate' Our website is the place for the latest breaking news, exclusive scoops, longreads and provocative commentary. Please bookmark and sign up for our cookbook and recipe newsletter, Cook This, here.
Yahoo
a day ago
- Yahoo
CytoSorbents Updates U.S. FDA Regulatory Status of DrugSorb-ATR
FDA appeal decision found no issues with DrugSorb-ATR device safety but upheld the De Novo denial, and proposes a potential path forward for market authorization PRINCETON, N.J., Aug. 20, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, updates the regulatory status of its appeal with the U.S. Food and Drug Administration (FDA) for De Novo market authorization of DrugSorb™-ATR. On August 14, 2025, the Company received an FDA appeal decision following its July 2025 in-person supervisory administrative review (appeal) meeting with FDA under 21 CFR 10.75. The appeal was in response to an April 25, 2025 FDA denial letter of the Company's De Novo application for DrugSorb-ATR. In the appeal decision, the FDA found no issues with device safety but upheld its prior De Novo denial decision citing the need for additional information to support the Company's desired label indication for this FDA Breakthrough Device. The FDA proactively proposed a potential path forward for market authorization of DrugSorb-ATR and the Company continues interactive discussions with the Agency to seek further clarity on this proposal. The FDA also noted another avenue for appeal to a higher level within the FDA, specifically with the Director of the FDA's Center for Devices and Radiologic Health (CDRH), that must be filed within 30 days of the appeal decision, which the Company is currently evaluating. "The path to FDA approval frequently involves sequential, collaborative discussions with the Agency to address issues that arise during the review process," stated Dr. Phillip Chan, Chief Executive Officer of CytoSorbents. "Although we are disappointed that the denial decision was upheld, we believe significant progress has been made with the resolution of the majority of outstanding issues previously raised by the FDA. Importantly, we have affirmed no issues of device safety on which the De Novo standard of a favorable benefit-to-risk profile is established. We appreciate the Agency's offer to find a path forward to market authorization that we plan to discuss with them further. We remain committed to continuing our collaborative interaction with the FDA to bring DrugSorb-ATR, an FDA Breakthrough Device, to the tens of thousands of heart attack patients in the U.S. each year who require urgent coronary artery bypass graft (CABG) surgery on ticagrelor. Today, these patients in the U.S. are either forced to delay their needed CABG surgery by many days while still having a heart attack, or face severe and potentially life-threatening perioperative bleeding. Given the millions of people around the world on blood thinners, perioperative bleeding represents an increasingly common and vexing problem for surgeons and their patients, each with a growing compendium of disaster stories. All of us unfortunately know a colleague, friend, spouse, parent, or other loved one on a blood thinner who has either faced or may face this risk of catastrophic bleeding. Our technology is being used around the world to address this risk, and our goal is to bring this important therapy to U.S. and Canadian surgeons and patients here at home." About CytoSorbents Corporation (NASDAQ: CTSO) CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. CytoSorbents' proprietary blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Cartridges filled with these beads can be used with standard blood pumps already found in hospitals (e.g. dialysis, continuous renal replacement therapy or CRRT, extracorporeal membrane oxygenation or ECMO, and heart-lung machines), where blood is repeatedly recirculated outside the body, through our cartridges where toxic substances are removed, and then back into the body. CytoSorbents' technologies are used in a number of broad applications. Specifically, two important applications are 1) the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and 2) the removal of inflammatory agents and toxins in common critical illnesses that can lead to massive inflammation, organ failure, and patient death. The breadth of these critical illnesses includes, for example, sepsis, burn injury, trauma, lung injury, liver failure, cytokine release syndrome, and pancreatitis, as well as the removal of liver toxins that accumulate in acute liver dysfunction or failure, and the removal of myoglobin in severe rhabdomyolysis that can otherwise lead to renal failure. In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments. CytoSorbents' lead product, CytoSorb®, is approved in the European Union and distributed in over 70 countries worldwide, with nearly 300,000 devices used cumulatively to date. CytoSorb was originally launched in the European Union under CE mark as the first cytokine adsorber. Additional CE mark extensions were granted for bilirubin and myoglobin removal in clinical conditions such as liver disease and trauma, respectively, and for ticagrelor and rivaroxaban removal in cardiothoracic surgery procedures. CytoSorb has also received FDA Emergency Use Authorization in the United States for use in adult critically ill COVID-19 patients with impending or confirmed respiratory failure. CytoSorb is not yet approved or cleared in the United States. In the U.S. and Canada, CytoSorbents is developing the DrugSorb™-ATR antithrombotic removal system, an investigational device based on an equivalent polymer technology to CytoSorb, to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs. It has received two FDA Breakthrough Device Designations: one for the removal of ticagrelor and another for the removal of the direct oral anticoagulants (DOAC) apixaban and rivaroxaban in a cardiopulmonary bypass circuit during urgent cardiothoracic procedures. In September 2024, the Company submitted a De Novo Request to the U.S. FDA requesting marketing approval to reduce the severity of perioperative bleeding in CABG patients on the antithrombotic drug ticagrelor, which was accepted for substantive review in October 2024. On April 25, 2025, the FDA issued a denial letter regarding the Company's De Novo Request for DrugSorb-ATR, identifying remaining deficiencies that must be addressed before the De Novo Request can be granted, and the device can be authorized for commercialization in the U.S. In July 2025, the Company had an in-person administrative appeal meeting with FDA under 21 CFR 10.75. The appeal hearing included FDA senior leadership and review team, Company management, its FDA regulatory counsel, and its external cardiac surgical experts. On August 14, 2025, the FDA issued a response to the Company's appeal that found no issues with device safety but upheld its prior De Novo denial decision citing the need for additional information to support the Company's desired label indication for this FDA Breakthrough Device. FDA proactively proposed a potential path forward for market authorization of DrugSorb-ATR and the Company continues interactive discussions with the Agency to seek further clarity on this proposal. The FDA also noted another avenue for appeal to a higher level within the FDA, specifically with the Director of the FDA's Center for Devices and Radiologic Health (CDRH) that must be filed within 30 days of the appeal decision, which the Company is currently evaluating. In November 2024, the Company received its MDSAP certification and submitted its Medical Device License (MDL) application to Health Canada. On June 26, 2025, Health Canada issued a Notice of Refusal of the Company's Medical Device License application, identifying remaining deficiencies that must be addressed before the application may be granted and the device authorized for commercialization. As part of Health Canada's prescribed reconsideration process, and after discussions with Health Canada, the Company has filed a Level 1 "Request for Reconsideration" and with agreement from the Medical Devices Directorate Bureau Director, will pursue the review following the completion of the Company's review with the U.S. FDA. DrugSorb-ATR is not yet granted or approved in either the United States or Canada. The Company has numerous marketed products and products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and registered trademarks, and multiple patent applications pending, including ECOS-300CY®, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™, DrugSorb™, ContrastSorb, and others. For more information, please visit the Company's website at or follow us on Facebook and X. Forward-Looking Statements This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, future targets and outlooks for our business, representations and contentions, and the outcome of our regulatory submissions, and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, our restructuring of our direct sales team and strategy in Germany, our ability to resolve deficiencies in the FDA appeal decision and to identify a path forward for market authorization, our ability to resolve deficiencies in the Health Canada Notice of Refusal and/or successfully appeal Health Canada's decision, and the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 31, 2025, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws. U.S. Company Contact: Peter J. Mariani, Chief Financial Officer 305 College Road East Princeton, NJ 08540 pmariani@ Investor Relations Contact: Aman Patel, CFA & Adanna G. Alexander, PhD ICR Healthcare ir@ View original content to download multimedia: SOURCE CytoSorbents Corporation
Business Insider
2 days ago
- Business Insider
Little Mix's Jade Thirlwall says she faces a 'daily battle' not to go on Ozempic
Little Mix 's Jade Thirlwall says she is resisting Ozempic despite the public scrutiny around her body. In an interview with The Guardian published Saturday, the singer said that many of the negative comments she receives are about weight gain. "I have a daily battle with myself not to go on Ozempic," Thirlwall told The Guardian. "I don't judge people that do, but because I have a history of eating disorders, I don't know where taking something like that would end for me." Thirlwall said she had only been out of the hospital for a few months after treatment for anorexia when she auditioned for " The X Factor" in 2011 at 18. "Historically, if I've ever felt that something is out of my control, then restricting food has been a means of controlling my life in a very toxic way," she said. Little Mix was formed on "The X Factor" in 2011, comprising Thirlwall, Leigh-Anne Pinnock, Perrie Edwards, and Jesy Nelson. Nelson left the group in 2020 amid backlash over Blackfishing, and in 2022, the band went on hiatus to focus on their solo careers. Thirlwall said that much of the scrutiny around her body comes from people comparing her to her younger self. "Now I'm in my 30s and the healthiest I've ever been, but every time I post a picture, there are comments saying, 'She must be pregnant.' The sad thing is that it's usually women," Thirlwall said. "But people are used to seeing me in a group environment five or 10 years ago when I was stick-thin because I was in my early 20s with an eating disorder," she said. A representative for Thirlwall did not immediately respond to a request for comment sent by Business Insider outside regular hours. Ozempic and Wegovy are brand names for semaglutide, an injectable drug originally developed for diabetes. In 2021, the FDA approved semaglutide for use in weight management. The drug works by regulating hunger signals, allowing people to feel full while eating less. However, it has side effects such as nausea, diarrhea, and constipation. Some patients also reported feeling disgusted by the foods they used to enjoy. Dr. Francesco Rubino, the chair of metabolic and bariatric surgery at King's College London, told Business Insider in 2022 that it was common for people to regain the weight after stopping treatment. Several doctors also told Business Insider in July that they've seen a sharp increase in patients on GLP-1 medications when they enter treatment for eating disorders. In recent years, many Hollywood celebrities have addressed speculation about whether they've used weight-loss drugs. In May 2023, NBA star Charles Barkley said he lost over 60 pounds in six months after taking Mounjaro while eating healthily and exercising. Later that year, in December 2023, Oprah Winfrey said she uses weight-loss medication to help manage her weight. Meanwhile, stars such as Lizzo, Kelly Clarkson, and Jesse Plemons, have denied using such medications, attributing their weight loss instead to lifestyle changes.
